Sanofi’s New R&D Chief: An AI-Powered Prescription for Growth?

PARIS, France – June 22, 2026 – In a move that signals a significant strategic pivot, French pharmaceutical giant Sanofi has appointed Dr. Paulo Fontoura, a veteran drug developer with deep expertise in artificial intelligence, as its new Global Head of Research & Development. The appointment, effective September 1, comes as the company seeks to revitalize its drug pipeline following recent setbacks and fully commits to its ambition of becoming the first major biopharma company powered by AI at scale. Dr. Fontoura, who most recently served as Chief Medical Officer at the AI-native biotech Xaira Therapeutics, will succeed Dr. Houman Ashrafian, who is departing the company.

This leadership change is more than a simple executive shuffle; it represents a calculated bet on a future where drug discovery is inextricably linked with computational power. For Sanofi, which has invested heavily in digital infrastructure, the arrival of a leader directly from the bleeding edge of AI-driven biology is a clear statement of intent. The challenge for Fontoura will be to translate that intent into a tangible, productive, and profitable R&D engine.

A Calculated Bet on an AI-Native Future

Dr. Fontoura’s most recent role at Xaira Therapeutics, a well-funded startup launched with the express purpose of using generative AI to reinvent drug creation, places him at the vanguard of a paradigm shift in biopharma. His appointment to lead Sanofi's entire innovation engine—from basic research to regulatory affairs—is a powerful signal that the company is moving beyond merely incorporating AI as a tool and is instead embedding it as a core operating principle. This move is designed to accelerate Sanofi's existing strategy, which CEO Paul Hudson has described as a mission to become "the first biopharma company powered by AI at scale."

Sanofi is not starting from zero. The company has been aggressively building its AI capabilities through a network of high-stakes partnerships. A deepened collaboration with Owkin aims to build autonomous AI 'scientists' directly into R&D workflows. A pioneering alliance with OpenAI and Formation Bio is focused on creating custom AI models using Sanofi's proprietary data. Furthermore, a partnership with BioMap, potentially worth over $1 billion, leverages large language models to design novel biologic therapies. Internally, the company has deployed proprietary platforms like 'PLai' to analyze over a billion data points for portfolio investment decisions and predict trial success rates.

Fontoura’s arrival is intended to be the catalyst that fuses these disparate initiatives into a cohesive and potent force. His experience at Xaira, which aims to use AI to predict biological targets and design therapeutics from the ground up, provides him with a unique perspective. He is not just an executive who understands AI, but a leader who has been immersed in building a company around it. "I am thrilled to join Sanofi at such an exciting moment," Fontoura stated in the official announcement, highlighting the company's "clear commitment to scientific innovation and AI-powered transformation."

A Mandate to Recharge a Pressured Pipeline

The strategic emphasis on AI is amplified by the immediate pressures facing Sanofi's R&D organization. The timing of Fontoura’s appointment is critical, following the company's recent decision to halt a late-stage study for an experimental treatment for a rare immune disorder after concluding it was unlikely to meet its efficacy goals. Such setbacks, while common in the high-risk world of drug development, place immense pressure on leadership to demonstrate a path toward renewed productivity.

Here, Fontoura's track record at Roche, one of the industry's most respected R&D organizations, becomes paramount. During his more than 15-year tenure, he played a leading role in a division that contributed to the development of over 60 new molecular entities. This work led to more than 20 first approvals from the FDA and EMA for breakthrough therapies targeting conditions like Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and Neuromyelitis Optica Spectrum Disorder (NMOSD). His deep experience in immunology, neuroscience, and rare diseases aligns directly with Sanofi's core therapeutic areas and strategic priorities.

In her statement, Sanofi CEO Belén Garijo emphasized this dual expertise, noting that Fontoura’s "scientific expertise, development experience, and leadership of large-scale innovation organizations will be invaluable as we continue to advance our pipeline." The implicit message is that Fontoura is not just an AI theorist; he is a proven drug developer who has successfully navigated the complex journey from lab to market on numerous occasions. His mandate is clear: leverage his experience and the power of AI to improve the probability of success, reduce development timelines, and refill a pipeline that is the lifeblood of any pharmaceutical company.

The Physician-Scientist at the Helm

Beyond the headlines of AI and pipeline pressures lies a third crucial aspect of Fontoura's profile: his identity as a physician-scientist. As a board-certified neurologist with an MD and a PhD in Neuroimmunology from the New University of Lisbon, followed by postdoctoral training at Stanford, he brings a perspective rooted in both clinical practice and fundamental science. This background is increasingly seen as vital for leaders in an industry where understanding the deep biology of a disease is as important as managing a global clinical trial.

This clinical acumen is not just academic. At Roche, Fontoura was a pioneer in integrating digital health into clinical trials, validating the first digital endpoint for Duchenne Muscular Dystrophy and utilizing smartphone-based monitoring. This practical application of technology to improve data quality and the patient experience demonstrates a holistic view of innovation. It suggests a leader who understands that transforming R&D isn't just about faster computers in the lab, but also about smarter, more patient-centric approaches in the clinic.

As a Fellow of the American Academy of Neurology with over 80 peer-reviewed publications, his scientific credibility is firmly established. By placing a physician-scientist with deep AI fluency at the top of its R&D hierarchy, Sanofi is making a definitive statement about the type of leadership it believes is necessary to win in the next era of medicine. The expectation is that Dr. Fontoura will now apply that same forensic level of scientific and clinical scrutiny to Sanofi's global portfolio, chasing the miracles of science with a powerful new set of digital tools.